French medtech startup Raidium, which specialises in precision radiology, has raised $13 million in seed funding. The round was led by Newfund, which invested in Ramify and Kurma, with additional support from Founders Future, Galion.exe, and the European EIC fund.
With this new funding, Raidium intends to accelerate the global rollout of its technology. The company plans to open offices in the US to expand its network of partners and clients, strengthen its European operations, and pursue regulatory approvals for FDA and CE certifications.
Additionally, Raidium will intensify its R&D efforts to enhance its multimodal capabilities and grow its team. Over the coming months, the startup will double its workforce, adding 25 members across research, development, regulatory affairs, and commercial partnerships.
The need for precision diagnostics
The need for precision diagnostics is growing, yet radiologists face outdated tools that hinder efficiency and accuracy. With 3D modalities like MRIs and CTs, radiological workflows are increasingly complex, straining systems and raising burnout risks while affecting diagnostic precision.
In clinical trials, where imaging endpoints drive one-third of studies, traditional tools limit speed and flexibility by allowing only single measurements. AI solutions remain underutilized due to their fragmented scope and poor integration into workflows. Raidium’s technology, built for clinical trials and practice, offers a transformative leap, enabling faster, scalable, and precise insights for complex cases like whole-body diagnostics.
GPT of Radiology: World’s first AI foundation model
Founded in 2022 by Dr. Paul Hérent and Pierre Manceron, Raidium has developed the world’s first radiological AI-native foundation model, transforming precision radiology. Dubbed as the “GPT of radiology,” it enables the creation of an imaging biomarker factory for both clinical practice and research.
Radium provides detailed 3D segmentation, advanced measurements, and automated analysis of complex biomarkers with unprecedented speed, 2,500 times faster than manual methods. Its AI model can analyse the entire human body, addressing complex cases such as metastatic cancer spread across multiple organs, and virtual biopsies for liver diseases like NASH.
As a result, the platform enhances productivity and diagnostic accuracy while generating comprehensive, automated reports. By merging cutting-edge AI with user-friendly design, Raidium empowers radiologists with an unparalleled tool to set new standards in precision and efficiency.
Key partnerships
Since its debut, the company has attracted the interest from major players in both the pharmaceutical and medical research sectors. It has established partnerships with academic centres in France, including AP-HP, Centre Imagerie du Nord.
The company also secured its first contracts with pharmaceutical clients and won a 1-year mentoring program with Amgen – Biolabs Golden ticket. These early milestones highlight the growing demand for robust, integrated imaging solutions that bridge clinical and research needs.
What holds for the future?
Focused on scalable imaging biomarkers, Raidium addresses inefficiencies in diagnostics and clinical trials. With plans to double its workforce, strengthen R&D, and secure FDA/CE certifications, the company is poised to revolutionise radiology workflows with faster, integrated solutions.
Dr. Paul Herent, Raidium’s co-founder and CEO, commented: “As a radiologist and passionate about AI, I see firsthand how current solutions fail to truly supporting radiologists and, by extension, patients who rely on timely and accurate diagnoses. At Radium, our mission is to create a scalable, life-saving solution that transforms radiology into a more precise and accessible field.”
